Biopharmaceutics regulatory update

BIOP's Mitolactol (dibomodulcitol) received Orphan Drug designation to treat primary brain tumors. The Bellport, N.Y., company has completed a Phase III trial and expects to file an NDA in the first quarter of 1996. Mitolactol also has orphan designation for cervical cancer. ...